Ergomed Plc (LON:ERGO) is set to report results from the Phase IIa trial of lorediplon for insomnia around the end of 2016 after it has now completed recruiting.
The firm is developing the drug with partner Ferrer and has now attained 130 patients from 11 clinical sites across three European countries.
The trial is expected to finish in the fourth quarter.
Chief executive Dr Miroslav Reljanovic said it marked another important step in the drug's clinical development.
"Lorediplon previously demonstrated - in a phase advanced model of insomnia - a potential best-in-class efficacy profile in terms of sleep maintenance and sleep quality when compared to the market leader zolpidem.
"This would make a marked improvement in the lives of patients suffering from this disorder."
The trial will be a double-blind, randomized, placebo-controlled cross-over, dose finding study of two oral doses of lorediplon.
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem.